Large arrays of single-molecule aptamer-based sensors for rapid multiplexing of low-concentration analytes
Active Grant Awarded
- Award ID
- R01EB038928
- Recipient
-
The Trustees Of Columbia University In The City Of New York UEI QHF5ZZ114M72
- Awarding agency
-
National Institute of Biomedical Imaging and Bioenginering
National Institutes of Health, Department of Health and Human Services
- Obligated
- $677,046
Award facts
- Assistance listing
- 93.286 Discovery and Applied Research for Technological Innovations to Improve Human Health
- Completion date 5% complete
- Place of performance
- New York, NY 10032, USA
Award details come from USAspending.gov.
About this award
The National Institutes of Health's National Institute of Biomedical Imaging and Bioengineering, within the Department of Health and Human Services, awarded Grant R01EB038928 to The Trustees of Columbia University in the City of New York, doing business as Health Sciences Division, obligating $677,046 on September 9, 2026. The award funds research under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), which supports hypothesis-, design-, technology-, or device-driven research on biomedical imaging and bioengineering technologies.
The recipient will develop large arrays of stochastic, single-molecule sensors for rapid, multiplexed quantification of low-concentration analytes under 5 kD, including vasopressin, angiotensin I, and catecholamines, in clinically relevant fluids without pretreatment and within minutes. The sensors combine individually point-functionalized carbon-nanotube single-molecule field-effect transistors with oligonucleotide aptamer receptors, and the project will integrate individually addressable sensors into arrays of up to a million sensors. The stated goal is pre-symptomatic monitoring of the neurohormonal axis that regulates blood pressure.
The period of performance runs from the September 9, 2026 award date to an ultimate completion date of May 31, 2030. Place of performance is New York, NY 10032.
Description
- Abstract
- We are pursuing rapid, multiplex quantification of low-concentration analytes with molecular weights under 5 KD. We define low concentrations as those in the pico- to low-nanomolar range, typical of clinically relevant, non- protein-bound components of the neurohormonal axis that prevent dramatic changes in blood pressure (i.e., the interplay of the sympathetic nervous, vasopressinergic, hypothalamic pituitary adrenal, and renin-angiotensin systems); these include vasopressin, angiotensin I, and catecholamines. For example, monitoring of this axis would allow pre-symptomatic recognition of a transition into capillary underfilling leading to deadly vasodilatory shock. Current assays for clinical decision-making, including LC-MS, hplc, elisa, and rias, require technical expertise, high-end instrumentation, and long turnaround times (often in days), preventing continuous assessment of the complex state as required to tailor interventions and prevent a loss of blood pressure. To overcome this analytical barrier, we will develop large arrays of stochastic, single-molecule sensors for quantification with high precision and accuracy within minutes in clinically relevant fluids, without any pretreatment. Our approach combines several scientific and technological breakthroughs: · individual point-functionalized carbon-nanotube (CNT) devices: these single-molecule field effect transistors (SMFETS) will continuously detect changes in the density of charged species at their surfaces. · oligonucleotide-based receptors (APTAMERS): these receptors will contract or expand upon ligand binding, generating the required changes in the density of charged species near the surfaces of SMFETS. · large-scale integration option: we will integrate individually addressable SMFETS into arrays of up to a million sensors (the limits of current capability). · simplified data acquisition and analysis: we will focus on digital transitions extracted from unique, ligand- specific signatures captured in the time domain, while eliminating the impact of any fleeting non-specific interactions that typically plague ensemble measurements. This approach will enable continuous, sub-second resolution of digital counts of receptor occupancy, leading to rapid quantification at concentrations several orders of magnitude below the dissociation constants of individual receptors, with minimal analyte depletion, and the ability to either prevent or filter out fingerprints of nonspecific interactions. By engineering aptamer structures, placing different aptamer patterns across arrays, and using multiple receptor variants for each target, we will address non-specific interactions and cross- reactivities. By the end of the funding period, we expect to have finalized and validated multi-analyte arrays based on these principles for at least four individual neurohormonal axis components, operating at clinically relevant concentrations and validated in the first set of clinical samples of interest.
Quick answers
Who received award R01EB038928?
R01EB038928 was awarded to The Trustees Of Columbia University In The City Of New York by National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health) on September 9, 2026.
How much is award R01EB038928 worth?
$677,046 has been obligated on R01EB038928.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award